Genetic Technologies (GENE) Receiving Somewhat Negative Press Coverage, Study Finds

Media stories about Genetic Technologies (NASDAQ:GENE) have been trending somewhat negative on Friday, Accern Sentiment Analysis reports. The research group identifies negative and positive press coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Genetic Technologies earned a news impact score of -0.12 on Accern’s scale. Accern also assigned media headlines about the biotechnology company an impact score of 0 out of 100, meaning that recent press coverage is extremely unlikely to have an effect on the stock’s share price in the near term.

Here are some of the news stories that may have effected Accern Sentiment’s rankings:

Shares of Genetic Technologies (NASDAQ GENE) traded down 1.1526% during midday trading on Friday, reaching $0.8319. 54,525 shares of the company’s stock were exchanged. Genetic Technologies has a 12-month low of $0.75 and a 12-month high of $2.89. The stock’s market cap is $13.51 million. The stock’s 50 day moving average is $0.86 and its 200-day moving average is $1.05.

WARNING: “Genetic Technologies (GENE) Receiving Somewhat Negative Press Coverage, Study Finds” was first reported by Markets Daily and is the property of of Markets Daily. If you are accessing this piece on another site, it was stolen and reposted in violation of U.S. and international copyright and trademark law. The original version of this piece can be read at https://www.themarketsdaily.com/2017/08/04/genetic-technologies-gene-earning-somewhat-critical-news-coverage-study-finds-updated-updated-updated.html.

Genetic Technologies Company Profile

Genetic Technologies Limited is a molecular diagnostics company. The Company is engaged in the provision of molecular risk assessment for cancer. The Company offers predictive testing and assessment tools for physicians to manage women’s health. The Company’s lead product, BREVAGenplus, is a clinically validated risk assessment test for non-hereditary breast cancer.

Insider Buying and Selling by Quarter for Genetic Technologies (NASDAQ:GENE)

Receive News & Ratings for Genetic Technologies Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genetic Technologies Ltd and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply